Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
A major obstacle for the effective treatment of pancreatic ductal adenocarcinoma (PDAC) is its molecular heterogeneity, reflected by the diverse clinical outcomes and responses to therapies that occur. The tumors of patients with PDAC must therefore be closely examined and classified before treatmen...
| Glavni autor: | |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Elsevier
2021-01-01
|
| Serija: | Translational Oncology |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S1936523320304575 |